Europe Companion Diagnostics Market was worth USD 0.91 million in 2018 and estimated to be growing at a CAGR of 20.66%, to reach USD 2.32 million by 2023 The continued expansion of companion diagnostics will also have a global module as markets in Europe will develop in a similar but not identical pattern as the US.
Companion diagnostics are an essential part of modified medicine and will likely continue to rapidly rise in number and application to disease areas. Companion diagnostics and targeted therapeutics are the pillars of personalised medicine. Aspects of genetic testing are used for testing possible abnormalities and modifying the treatment so as to make it as personalized as the disease itself.
A major driver for growth of the market will continue to be the economic reasons for drug developers to pair their products with diagnostics. Restricted regulatory barriers for drug and diagnostic combination products, which the current IVD directive classifies under the low-risk category, are accelerating market access. One of the greatest challenges to future growth in companion diagnostics is supporting the inducements of all stakeholders.
The Europe clinical nutrition market is segmented on the basis of indication into Oncology (Colorectal Cancer, Breast Cancer, Lung Cancer, Melanoma, and Gastric Cancer), Cardiovascular Diseases, Central Nervous System Disorders, Inflammation and Virology Diseases. Further, Oncology is sub-segmented as Colorectal Cancer, Breast Cancer, Lung Cancer, Melanoma, and Gastric Cancer. Oncology being the highest revenue creating segment as most of the companion diagnostics has been developed to detect one or the other cancer biomarkers. On the basis of technology, the market is bifurcated into Immunohistochemistry and molecular diagnostics. Molecular diagnostics is segmented into in-situ hybridization, real time PCR and gene sequencing.
Based on geography the European market is analysed under various regions namely, Germany, U.K, Spain, Italy and France. With the increasing initiatives from government Germany is growing at the highest rate in this region.
Some of the key participating global players in companion diagnostics market global market are Abbott Molecular Inc., Roche Molecular Systems Inc., Leica Biosystems Nussloch GmbH, bioMérieux Inc., Dako Inc., Qiagen Ltd., ARUP Laboratories, Myriad Genetics Inc.,Biogenex Laboratories Inc., Ventana Medical Systems Inc., Thermo Fisher Scientific Inc. and others.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Indications
5.1.1 Oncology
5.1.1.1 Colorectal Cancer
5.1.1.2 Breast Cancer
5.1.1.3 Lung Cancer
5.1.1.4 Gastric Cancer
5.1.1.5 Melanoma
5.1.2 Inflammation and Autoimmune Diseases
5.1.3 Cardiovascular Diseases
5.1.4 Central Nervous System Disorders
5.1.5 Virology Diseases
5.2 By Technology
5.2.1 Immuno Histochemistry
5.2.2 Molecular Diagnostics
5.2.2.1 In-Situ Hybridization
5.2.2.2 Real Time PCR
5.2.2.3 Gene Sequencing
6. Geographical Analysis
6.1 Introduction
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Abbott Molecular Inc.
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Roche Molecular Systems Inc.
8.3 Leica Biosystems Nussloch GmbH
8.4 BioMérieux Inc.
8.5 Dako Inc.
8.6 Qiagen Ltd.
8.7 ARUP Laboratories
8.8 Myriad Genetics Inc.
8.9 Biogenex Laboratories, Inc.
8.10 Ventana Medical Systems Inc.
8.11 Thermo Fisher Scientific Inc.
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Expert Opinions
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
